SCN5A and cardiac rhythm disease: This insight was first gained in the landmark Cardiac Arrhythmia Suppression Trial in which patients randomized to the class 1c cardiac antiarrhythmic drugs (potent Nav1.5 blockers) flecainide or encainide suffered excess mortality rates due to SCD compared to placebo-treated patients [10].